318 related articles for article (PubMed ID: 29498210)
1. A multicenter, observational study of metastatic breast cancer patients who were treated with eribulin mesylate or taxane-based regimens.
Kikuchi Y; Uchida Y; Shirakawa K; Kanauchi H; Niwa T; Nishioka K; Tada K; Hashimoto M; Yasuda H; Sugiura R; Kawabata H; Seto Y; Ogawa T
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e231-e237. PubMed ID: 29498210
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
3. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
Lorusso V; Cinieri S; Latorre A; Porcu L; Del Mastro L; Puglisi F; Barni S
Future Oncol; 2017 May; 13(11):971-978. PubMed ID: 28326833
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Twelves C; Cortes J; Vahdat L; Olivo M; He Y; Kaufman PA; Awada A
Breast Cancer Res Treat; 2014 Dec; 148(3):553-61. PubMed ID: 25381136
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
[TBL] [Abstract][Full Text] [Related]
10. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Hardy-Bessard AC; Brocard F; Clatot F; Lortholary A; You B; Grenier J; Martin-Babau J; Lucas B; Meunier J; Ferrero JM; Savoye AM; Marti A; Despax R; Moullet I; Emile G
Breast; 2020 Dec; 54():256-263. PubMed ID: 33188992
[TBL] [Abstract][Full Text] [Related]
11. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
[TBL] [Abstract][Full Text] [Related]
12. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
13. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
15. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
17. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
[TBL] [Abstract][Full Text] [Related]
18. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
19. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
